Novartis AG
NVS119.450USD
-1.280-1.06%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
234.03BValor de mercado
19.60P/L TTM
Mais detalhes de Novartis AG Empresa
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Informações da empresa
Código da empresaNVS
Nome da EmpresaNovartis AG
Data de listagemMay 07, 2001
Fundado em1996
CEODr. Vasant (Vas) Narasimhan, M.D.
Número de funcionários75883
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 07
EndereçoLichtstrasse 35
CidadeBASEL
Bolsa de valoresJohannesburg Stock Exchange
PaísSwitzerland
Código postal4056
Telefone41613241111
Sitehttps://www.novartis.com/
Código da empresaNVS
Data de listagemMay 07, 2001
Fundado em1996
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
Por RegiãoUSD
Nome
Receita
Proporção
United States
21.15B
42.03%
Other Foreign-
18.51B
36.79%
China
3.89B
7.73%
Germany
3.66B
7.27%
France
1.79B
3.56%
Switzerland
1.31B
2.61%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Dodge & Cox
0.60%
PRIMECAP Management Company
0.53%
Dimensional Fund Advisors, L.P.
0.44%
Fisher Investments
0.35%
Loomis, Sayles & Company, L.P.
0.28%
Other
97.80%
Investidores
Investidores
Proporção
Dodge & Cox
0.60%
PRIMECAP Management Company
0.53%
Dimensional Fund Advisors, L.P.
0.44%
Fisher Investments
0.35%
Loomis, Sayles & Company, L.P.
0.28%
Other
97.80%
Tipos de investidores
Investidores
Proporção
Investment Advisor
3.16%
Investment Advisor/Hedge Fund
3.00%
Research Firm
0.50%
Hedge Fund
0.33%
Bank and Trust
0.11%
Pension Fund
0.03%
Family Office
0.01%
Other
92.84%
Participação acionária institucional
Atualizado em: qui, 20 de fev
Atualizado em: qui, 20 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
1921
132.66M
6.77%
-8.92M
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
2023Q1
1762
167.49M
7.98%
-13.01M
2022Q4
1782
173.67M
8.19%
-17.15M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Dodge & Cox
12.21M
0.62%
-7.21K
-0.06%
Dec 31, 2024
PRIMECAP Management Company
11.03M
0.56%
-983.02K
-8.19%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
8.18M
0.41%
+90.82K
+1.12%
Dec 31, 2024
Fisher Investments
2.00M
0.1%
+296.95K
+17.41%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
5.58M
0.28%
-192.68K
-3.34%
Dec 31, 2024
Franklin Mutual Advisers, LLC
4.26M
0.22%
-16.98K
-0.40%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
3.59M
0.18%
-52.88K
-1.45%
Dec 31, 2024
Parametric Portfolio Associates LLC
2.98M
0.15%
-86.17K
-2.81%
Dec 31, 2024
Wellington Management Company, LLP
3.65M
0.18%
-351.31K
-8.78%
Dec 31, 2024
Managed Account Advisors LLC
2.95M
0.15%
-214.17K
-6.76%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
VanEck Pharmaceutical ETF
4.58%
Amplify International Enhanced Dividend Income ETF
3.56%
Altrius Global Dividend ETF
2.74%
Abacus FCF International Leaders ETF
2.7%
Invesco International Dividend Achievers ETF
2.28%
Pacer Global Cash Cows Dividend ETF
2.24%
Freedom Day Dividend ETF
2.08%
SP Funds S&P World (ex-US) ETF
1.8%
Brandes International ETF
1.65%
SGI Enhanced Global Income ETF
1.52%
Ver Mais
VanEck Pharmaceutical ETF
Proporção4.58%
Amplify International Enhanced Dividend Income ETF
Proporção3.56%
Altrius Global Dividend ETF
Proporção2.74%
Abacus FCF International Leaders ETF
Proporção2.7%
Invesco International Dividend Achievers ETF
Proporção2.28%
Pacer Global Cash Cows Dividend ETF
Proporção2.24%
Freedom Day Dividend ETF
Proporção2.08%
SP Funds S&P World (ex-US) ETF
Proporção1.8%
Brandes International ETF
Proporção1.65%
SGI Enhanced Global Income ETF
Proporção1.52%
Dividendo
Um total de
36.74B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Feb 20, 2025
NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025
Mar 12, 2025
May 01, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
